Nancy E. Messonnier, MD is director of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention (CDC) and leads the CDC’s efforts on COVID-19 vaccination. She joins JAMA's Q&A series to discuss the agency's response to emerging coronavirus variants, the FDA advisory hearings on the new Johnson & Johnson vaccine, and other agency activities and priorities related to COVID-19 control. Recorded February 26, 2021.

Related Content:

• Genetic Variants of SARS-CoV-2—What Do They Mean?
• Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD
• SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
• Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More
• Emergence of a Novel SARS-CoV-2 Variant in Southern California
• SARS-CoV-2 Variants of Concern in the United States
• Pregnant People Getting Mixed Messages About COVID-19 Vaccines
• The Johnson & Johnson Vaccine for COVID-19
• SARS-CoV-2 Viral Variants—Tackling a Moving Target
• Vaccine Distribution—Equity Left Behind?
• Taking Vaccine to Where the Virus Is—Equity and Effectiveness in Coronavirus Vaccinations?

Interview with Richard Saitz, MD, author of Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough and with Yngvild Olsen, MD, author of Overcoming Barriers to Treatment of Opioid Use Disorder

Interview with Ik-Kyung Jang, MD, PhD, author of New Insights Into Plaque Erosion as a Mechanism of Acute Coronary Syndromes

CDC Director Rochelle P. Walensky, MD, MPH, returns to JAMA's Q&A series to discuss the agency's response to emerging SARS-CoV-2 variants, implications for the planned vaccine mobilization strategy, the upcoming Johnson & Johnson vaccine FDA advisory hearings, strategies for reopening K-12 schools, and other agency activities and priorities related to COVID-19 control. Recorded February 17, 2021.

Related Article(s):

• Coronavirus Update With CDC Director Rochelle Walensky - February 17, 2021
• SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities
• SARS-CoV-2 Viral Variants—Tackling a Moving Target

Paul A. Offit, MD, of The Children's Hospital of Philadelphia returns to JAMA's Q&A series to provide an update on the emergence of COVID-19 variants and their implications for vaccine development, including the Johnson & Johnson vaccine, scheduled for a US Food and Drug Administration VRBPAC hearing on February 26, 2021. Recorded February 11, 2021.

Related Article:

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

As US vaccine distribution expands to include younger healthier populations, questions about vaccine safety in women of childbearing age have become more urgent. University of Texas Southwestern Medical Center's Catherine Y. Spong, MD, and Emory University School of Medicine's Denise J. Jamieson, MD, MPH, both eminent obstetrician/gynecologists, join JAMA's Q&A series to discuss the safety of the Pfizer-BioNTech and Moderna vaccines in pregnant and nursing mothers, and in individuals trying to get pregnant. Recorded February 8, 2021.

Related Article(s):

• Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021
• COVID-19 Vaccination in Pregnant and Lactating Women
• Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines

Interview with Lawrence O. Gostin, JD, author of Mandating COVID-19 Vaccines

2021 has brought news of emerging SARS-CoV-2 genetic variants that increase transmissibility. Will they diminish vaccine efficacy and lead us to lose pandemic control? University of Michigan's Adam Lauring, MD, PhD, a molecular virologist who uses evolutionary theory to study viral transmission and pathogenesis, joins JAMA's Q&A series to explain the variants and what they mean for public health. Recorded February 4, 2021.

Related Article(s):

Genetic Variants of SARS-CoV-2—What Do They Mean?

Interview with Donald Berwick, MD, author of The Triple Aim Applied to Correctional Health Systems

NIAID Director Anthony S. Fauci, MD, returns to JAMA's Q&A series to discuss

• Shifts in the US pandemic response under the Biden administration
• Emerging genetic variants and implications for vaccine efficacy
• Prospects for new vaccine approvals and more.

Related Article:

Preventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions